Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
"Cash runway (excluding dx sale) until 2026 allows Avacta to prove efficacy for 6k as well as brings other assets to clinic. TMAC in particular is highly exciting."
Reality is existing cash (after EGM) will need topping up in 12-18 months, however negotiating is about showing you are able to do it when you can and showing willingness to undertake DX sale together with displaying potential NASDAQ serves a purpose there - they might not happen but it's important that AVCT demonstrate they are prepared to take the hard decisions in time if they need too.
In the meantime 12 months for SB to negotiate away on side deals
GLA
"No worries WAG, one other point, we are also awaiting what the percentage of ownership we have for that South Korean Company, if that has a 100mkt cap on IPO and we own 25% that’s a 25 million injection. Plenty of strategic options available for the future not just DX getting sold."
Avacta wont sell when Affyexell raise.
"So have 19.3m new deferred shares just been confirmed today – plus 250k normal shares"
Nope it's a very old historic reference on each companies house announcement on share issues.
Ps it's largely the reason they ballsed up the total shares in issue in the 22nd January RNS
“… UP TO a value of £3,000 per employee”
“… an additional 9,515 Ordinary Shares have been issued”
Couldn’t be any clearer, @AVCT.
"will be issued at the prevailing middle market price at the close of business on 14 February 2024 to all eligible employees"
Could be much clearer @ StarBright
Maybe while they are doing their correction they could clarify why £3,000 / 9,515 = 31.53p rather than 95p odd.
It's very odd but sometimes AVCT do seem to go out of their way to be ambiguos - why not for clarity just state the total number of SIP shares issued.
Take a look at NASDAQ listed Bicycle Therapuetics who have an inferior drug delivery platform.
Multiple candidates in early stage clinical and two multi billion $ collaborations, combined up front cash elements $95m ( Novartis and Bayer )
MV after deducting cash on balance sheet £115m!
In my view very very difficult to compare this voyager deal with what Avacta might do. Avacta I would like to think have more optionality despite less cash.
This looks like a follow on from March 2022 option deal - but not researched in detail.
@JT
Not sure I agree that inference is correct. If your view is correct, why don't ADCs cleave all over the place and have much wider adverse side effects.
We already knew the importance of Precision attacking the Stroma, courtesy of Elliot at the AGM
@JT "Summary: ADCs are better when they release (some of) their warhead in the tumour micro environmen"
Is that summary in the article or your own summary?
My research into ADCs suggested bystander killing ( and some systemic warhead ) arose from leakage of the cytotoxix warhead released in the cancer cell
@JT how timely that investor meet Q&A published this evening - question 2:
Could you clarify whether or not the format of the planned fortnightly dosing study will be a continuation of the Phase 1a dose escalation study? Meaning: - taking patients who, largely, have exhausted their existing lines of treatment (i.e. NOT a first line treatment study)? - taking patients with the same range of cancers as in the original study - so including breast, ovarian, colorectal, etc. - in order to gain more efficacy data for those other cancers that would be useful in licensing deal negotiations (i.e. NOT limited to STS)?
The two-weekly dosing study will aim to take patients with a more defined set of cancers than was the case in the three-weekly study and these may also have different treatment histories. This is designed to help further inform the choice of indications for the Phase 2 study. If it is possible to enrol patients earlier in their treatment journey then that is a decision for the treating oncologist.
Hi JT I'll take your last as a guess.
I've just reread the zTG meeting note posted by somebody:
The first question, a multiparter included "...what does a first line treatment mean."
I didn't see a reply to that part reoprted.
I'm afraid a liitle sceptical, but note that you belive this.
".. during the "Telegram Group meeting with AS and FMcL". He clarified that these would still be late stage patients, just those that hadn't undergone too much previous chemical treatments...."
Did you/telegram have an explanation why - seems counterproductive ?